Protalix BioTherapeutics, Inc. filed a Form 10-Q with the SEC on November 10, 2026, reporting unaudited condensed consolidated financial results for the quarterly period ended September 30, 2026.

Key Highlights

  • Total revenue of $75,571 thousand for the nine months ended September 30, 2026, compared to $43,622 thousand for the same period in 2025, according to the filing.
  • Net income of $26,055 thousand for the nine months ended September 30, 2026, versus a net loss of $1,100 thousand for the nine months ended September 30, 2025.
  • Revenues from license and R&D services were $26,490 thousand for the nine-month period, compared to $514 thousand in the prior-year period, the filing disclosed.
  • Total assets increased to $118,242 thousand as of September 30, 2026, up from $82,346 thousand as of December 31, 2025.
  • Stockholders' equity rose to $80,549 thousand at September 30, 2026, from $48,230 thousand at January 1, 2026.
  • Approximately 84,318,923 shares of common stock were outstanding as of November 1, 2026, the registrant reported.
  • Basic earnings per share of $0.33 for the nine months ended September 30, 2026, compared to a loss of $0.01 per share for the same period in 2025.

Protalix BioTherapeutics Q3 2026 Financial Results: Revenue and Income Detail

Protalix BioTherapeutics, Inc. (NYSE American:PLX) reported total revenue of $75,571 thousand for the nine months ended September 30, 2026, according to the filing. This compares to $43,622 thousand for the nine months ended September 30, 2025. The filing shows revenues from selling goods of $49,081 thousand and revenues from license and R&D services of $26,490 thousand for the nine-month period, versus $43,108 thousand and $514 thousand, respectively, in the prior-year period.

For the three months ended September 30, 2026, the company disclosed total revenue of $21,925 thousand and net income of $3,961 thousand, compared to total revenue of $17,851 thousand and net income of $2,355 thousand for the three months ended September 30, 2025. Operating income for the nine-month period was $29,865 thousand, against an operating loss of $842 thousand in the comparable prior-year period. Cost of revenues for the nine months ended September 30, 2026 was $19,765 thousand, down from $22,374 thousand in the same period of 2025.

On the balance sheet, cash and cash equivalents stood at $22,035 thousand and short-term bank deposits at $26,503 thousand as of September 30, 2026, compared to $14,680 thousand and $15,593 thousand, respectively, at December 31, 2025. Inventories increased to $34,297 thousand from $25,729 thousand over the same period. The company also reported a new R&D grant receivable of $3,030 thousand as a non-current asset at September 30, 2026, which was not present at December 31, 2025. During the nine months ended September 30, 2026, the company issued 1,613,992 shares under its Sales Agreement, net of costs, for proceeds of $4,210 thousand, and recorded 453,296 shares from option exercises for $523 thousand, the filing stated.

What Was Disclosed

The filing covers Protalix BioTherapeutics' unaudited financial statements for the nine and three months ended September 30, 2026, including the balance sheet as of that date, income statements, statements of changes in stockholders' equity, and cash flow statements, together with related notes and management discussion.